New Drug Approved for Early Alzheimer's
What is the new Alzheimer's drug approved by the FDA?
The FDA has approved a new Alzheimer's drug called donanemab, to be sold under the brand name Kisunla by Eli Lilly. It is part of a novel class of treatments and has been shown in studies to modestly slow the pace of cognitive decline in early stages of the disease. However, it also carries significant safety risks, including swelling and bleeding in the brain.
What is the brand name of the newly approved drug donanemab?
The newly approved drug donanemab will be sold under the brand name Kisunla. It is made by Eli Lilly and has been shown to modestly slow the pace of cognitive decline in early stages of Alzheimer's disease1.
How does Kisunla affect early-stage Alzheimer's cognitive decline?
Kisunla, an early Alzheimer's treatment by Eli Lilly, has been approved by the FDA. In an 18-month study, patients given Kisunla declined about 22% more slowly in terms of memory and cognitive ability compared to those who received a placebo4. The drug targets and removes amyloid plaques, which are associated with Alzheimer's disease progression.